# Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025
Canonical URL: https://biopharmsignal.com/news/BMEA/biomea-fusion-announces-kol-presentation-and-interview-on-menin-and-icovamenib-at-wcirdc-2025
Ticker: BMEA
Company: Biomea Fusion
Source: Biomea Fusion
Published: 2025-12-09 23:36 EST
Original Source URL: https://investors.biomeafusion.com
## Summary

Key Opinion Leader, Dr. Ralph DeFronzo presents the “Future of Menin Inhibitors” and discusses icovamenib and its clinical results shared during WCIRDC 2025 in online interview SAN CARLOS, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical stage diabetes and

## Article Body
Key Opinion Leader, Dr. Ralph DeFronzo presents the “Future of Menin Inhibitors” and discusses icovamenib and its clinical results shared during WCIRDC 2025 in online interview SAN CARLOS, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical stage diabetes and
## Recent Company News
- 2026-06-03 12:00 EST — [Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity](https://biopharmsignal.com/news/BMEA/biomea-fusion-announces-research-collaboration-with-university-of-leicester-to-evaluate-icovamenib-in-combination-with-semaglutide-in-obesity) — Source: Biomea Fusion
- 2026-05-11 20:55 EST — [Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights](https://biopharmsignal.com/news/BMEA/biomea-fusion-reports-first-quarter-2026-financial-results-and-corporate-highlights) — Source: Biomea Fusion
- 2026-05-05 21:51 EST — [Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions](https://biopharmsignal.com/news/BMEA/biomea-fusion-announces-poster-presentations-of-icovamenib-at-the-american-diabetes-association-ada-86th-scientific-sessions) — Source: Biomea Fusion
- 2026-04-27 21:37 EST — [Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment](https://biopharmsignal.com/news/BMEA/biomea-fusion-announces-positive-52-week-results-from-phase-2-covalent-112-trial-in-type-1-diabetes-showing-c-peptide-improvement-and-durability-following-12-weeks-of-icovamenib-treatment) — Source: Biomea Fusion
- 2026-03-31 11:00 EST — [Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies](https://biopharmsignal.com/news/BMEA/biomea-fusion-announces-first-patient-dosed-in-newly-initiated-phase-ii-programs-enrolling-type-2-diabetes-patients-failing-on-standard-of-care-therapies) — Source: Biomea Fusion
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)